News

Bioenvision will receive milestone payments and a percentage of Mayne's net sales revenue. Mayne Pharma is responsible for securing regulatory approval and government reimbursement in Australia and New

Analysis of data from the trial indicates that, so far, 21% of patients in the trial have achieved either a clinical response to treatment or stabilization of their

The study was designed to evaluate the protective effect of MU1140 when administered by intravenous injection to mice infected intraperitoneally with a lethal dose of Staphylococcus aureus. The

The designation provides Oxigene with several potential benefits for combretastatin A4P (CA4P), including a guarantee of seven years of market exclusivity upon approval in the ovarian cancer indication.

The trial examines the safety and potential efficacy for pixantrone when substituted for mitoxantrone in the established FND-R chemotherapy regimen for non-Hodgkin's lymphoma (NHL) patients who had failed

The proposals, which were passed on a second vote in the EU parliament, will require specific thresholds for claims such as 'low fat', 'high fiber' or 'reduced sugar'.

Roche will provide technical know-how to assist Aspen in the production and registration of the generic product, and also supply the active pharmaceutical ingredient to the African company.

The primary objective of this study is to determine the maximum tolerated dose for satraplatin in combination with Xeloda in patients with advanced solid tumors. The trial is

The new approval expands the indication for the drug, which is already approved for use in the treatment of partial onset epileptic seizures. Juvenile myoclonic epilepsy (JME) is